Latest news

Grand succès du Challenge Debiopharm Inartis

Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer

FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer

Yakult Honsha Co., Ltd. and Debiopharm International SA File Patent Infringement for Elplat® against Nippon Kayaku Co., Ltd.

Debiopharm Group™ donates to IMD to promote best practice in family business philanthropy

Debiopharm Investment SA acquires famous Parisian restaurants in partnership with GROUPE BERTRAND and Galiena Capital

Debiopharm International SA announces presentation at AACR of non-clinical data relating to its targeted investigational compound Debio 1347/CH5183284, a selective…

Debiopharm International SA to present the latest findings on Debio 1450 at ECCMID

Debiopharm International SA has won its Patent Infringement Suit for Elplat® against Nippon Kayaku Co., Ltd.